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Background: We aimed to evaluate whether oral anticoagulants (OACs) alter faecal immunochemical test (FIT) performance in
average-risk colorectal cancer (CRC) screening.
Methods: Individuals aged 50–69 years were invited to receive one FIT sample (cutoff 75 ngml–1) between November 2008 and
June 2011.
Results: Faecal immunochemical test was positive in 9.3% (21 out of 224) of users of OAC and 6.2% (365 out of 5821) of non-users
(P-trend¼ 0.07). The positive predictive value (PPV) for advanced neoplasia (AN) in non-users was 50.4% vs 47.6% in
users (odds ratio, 0.70; 95% CI, 0.3–1.8; P¼ 0.5). The PPV for AN in OAC more antiplatelets (aspirin or clopidogrel) was 75%
(odds ratio, 2; 95% CI, 0.4–10.8; P¼ 0.4).
Conclusions: Oral anticoagulant did not significantly modify the PPV for AN in this population-based colorectal screening
program. The detection rate of advanced adenoma was higher in the combination OAC more antiplatelets.
The faecal immunochemical test (FIT) is one of the tests
recommended by different societies for colorectal cancer (CRC)
screening in average-risk populations (Levin et al, 2008). Faecal
immunochemical test is performed annually or biennially after age
50. In a recently published population-based, randomised trial,
FIT detected an equivalent number of CRC as colonoscopy in the
first CRC screening round (Quintero et al, 2012).
There is no consensus among experts about whether oral
anticoagulants (OACs) alone or in combination with antiplatelet
drugs should be suspended before stool collection for FIT
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(Levi et al, 2009; Sawhney et al, 2010; Mandelli et al, 2011).
Previous studies from our group have observed aspirin and
antiplatelets should not be stopped before FIT, as these drugs do
not diminish the positive predictive value (PPV) for advanced
neoplasia (AN; Bujanda et al, 2013).
The objective of this study was to determine whether the use of
OAC, alone or in combination with antiplatelet drugs, affects the
positivity and detection rates for AN in average-risk subjects
undergoing CRC screening.
MATERIALS AND METHODS
Study design. We performed a post hoc analysis of subjects
assigned to the FIT arm of the COLONPREV trial, a randomised
controlled study aimed at comparing one-time colonoscopy vs
biennial FIT for the reduction of CRC-related mortality at 10 years
in an average-risk population. The study, described in detail
elsewhere (Quintero et al, 2012), started in November 2008 and the
first round was completed in June 2011. Subjects agreeing to
participate in the study received an appointment to the local
screening office. The data manager conducted a questionnaire
(face to face) about taking drugs (type, dose and frequency).
Patients usually have a list of the drugs they take. At the time of the
interview, data manager explained how to make the FIT without
stopping any medication.
Faecal immunochemical test strategy consisted of a single
sample using the automated semiquantitative OC-Sensor kit (Eiken
Chemical Co., Tokyo, Japan), without any specific diet or
medication limitations. Patients with X75 ng haemoglobin per
ml of buffer solution (X15 mg of haemoglobin per gram of faeces)
were invited for a colonoscopy (Fraser et al, 2012).
Within this cohort, we defined the ‘users’ as those reporting
chronic use of OAC (acenocoumarol), alone or in combination
with antiplatelet drugs. Antiplatelet drugs were aspirin p300mg
day–1 or clopidogrel. The non-users group consisted of subjects not
taking any of these drugs, either chronically or sporadically, within
30 days of testing. Patients taking these drugs intermittently or
sporadically within 30 days of testing were excluded from the
analysis. Individuals taking new anticoagulants (dabigatran,
rivaroxaban, apixaban and edoxaban) or non-steroidal anti-
inflammatory drugs were also excluded. No change in medication
before stool collection was recommended.
Adenomas X10mm in size, with villous architecture,
high-grade dysplasia or intramucosal carcinoma were classified
as advanced adenomas. Advanced neoplasia was defined as
advanced adenoma or invasive cancer. Non-AN (NAN) were
classified as the presence of one or two small adenomas o10mm.
Invasive cancer was considered to exist when malignant cells were
observed beyond the muscularis mucosa. A specific program was
designed to ensure the quality of the whole process (Jover et al,
2012; Quintero et al, 2012).
Statistical analysis. Chi-square test and/or Fisher test was used to
compare categorical variables across the groups and one-way
ANOVA was used to compare continuous variables. Faecal
haemoglobin measurements are presented as medians and
compared using the non-parametric Kruskal–Wallis test. The
positivity rate and the PPV was calculated for the users and non-
users group.
RESULTS
Postal invitations to undergo FIT were sent to a total of 28 696
individuals, with a mean age of 59.5±5.5 years, 47% were men.
Of them 1054 (3.6%) invitations were returned unanswered.
In addition, 1043 (3.6%) were excluded either permanently or
temporarily. The eligible population consisted of 26 599 people.
A total of 10 611 (36.9%) individuals returned the test and 6045
(56.9%) fulfilled the questionnaire and reported adequate informa-
tion on the use of OAC (Figure 1). Mean age was 59.5±5.6 years
and 2803 (46%) were men. Of the 6045 participants, 5821 (96.3%)
reported not using any of these drugs (non-users group), and 224
(3.7%) reported taking OAC alone or in combination with
antiplatelet drugs before testing (users group). In the users group,
164 individuals reported taking OAC alone and 60 OAC in
combination with antiplatelet drugs. As expected, more men were
taking these drugs than women and age was higher in those taking
antiplatelet drugs than in non-users (Table 1). There were no
differences in the type or the location of lesions (CRC, AN and
NAN) between users and non-users group.
Faecal immunochemical test was positive for occult blood in 386
of 6045 participants (6.3%). Of the 386 people with positive test,
colonoscopy was normal in 124 (32%) cases, whereas 20 (5%) had
CRC, 174 (45%) AA and 68 (18%) NAN. Tumour staging of
identified lesions (FIT: stage I in 16; stage II in 2 and stage III in 2).
Faecal immunochemical test was positive in (21 out of 224)
9.3% of the users group and (365 out of 5821) 6.2% in the non-
users group (P-trend¼ 0.07; Table 2). The number of AN found in
the OAC more antiplatelet therapy users not differ significantly
with non-users (Table 3). The PPV for AN in OAC more
antiplatelets (aspirin or clopidogrel) was 75% (odds ratio, 2; 95%
CI, 0.4–10.8; P¼ 0.4). Median haemoglobin concentration detected
in the stool did not differ significantly between non-users and users
(285 ngml–1 vs 502 ngml–1; P-trend¼ 0.2).
The PPV for AN in the non-user group was 50.4% and 47.6%
(Table 4). The PPV for NAN was 50.4% (184 out of 365), 30.8%
(4 out of 13) and 75% (6 out of 8), in the non-users, OAC, and
OAC in combination with other drugs respectively, without
significant differences (P¼ 0.2).
DISCUSSION
The number of people with long-term OAC therapy is increasing.
In 2006, 4% of the population taking OAC (equal to our study) and
9% of those over 65 years (Dossett et al, 2011). Patients with
prosthetic heart valves, chronic or paroxysmal atrial fibrillation,
recurrent deep venous thrombosis, hypercoagulable diseases,
and vascular diseases are currently maintained on long-term
anticoagulants. Anticoagulation is mandatory to reduce the risk of
28 696 individuals assessed for eligibility
1054 not contacted 1043 excluded
26 599
6045 returned the FIT
and reported information on drugs and anticoagulants
5821 nonusers group
6.2% FIT positive (365/5821)
224 users group
9.3% FIT positive (21/224)
Figure 1. Study recruitment and participant flow.
FIT and OACs BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.38 1335
thromboembolism, but at the same time the therapy increases the
risk of bleeding.
In our study, the OAC alone or in combination with antiplatelet
drugs showed increased FIT positivity without increasing the false
positivity rate. The rate of positive for control, OAC and the
combination were 6.2%, 7.9% and 13.3%, respectively. There were
no statistically significant differences in the PPV for AN in
comparing with non-users. Only three studies (Levi et al, 2009;
Sawhney et al, 2010; Mandelli et al, 2011) have analysed the effect
of OAC on the FIT performance. A study (Levi et al, 2009)
includes 16 individuals taking warfarin, nevertheless, concluded
that anticoagulants were associated increased sensitivity with no
change in specificity for NA. Another study (Mandelli et al, 2011)
examines 53 patients taking OAC with positive FIT and compared
with 106 controls (positive FIT without OAC). Advanced neoplasia
was detected in 28.3% of cases and 34.9% of controls without
statistically significant difference. The third study (Sawhney et al,
2010) concluded that OAC reduces the PPV for AN compared
with controls (20% in OAC vs 30% in controls). However, this
study has some differences with our research, the number of
patients taking anticoagulants was lower (85 individuals), the test
used was the haemoccult II and patients were not a screening
program. In the latter study, the percentage of patients with CRC
and AN was low, 3.1% and 24%, respectively, probably due to the
test performed. In our study, the proportion of CRC and AN in
patients with positive FIT was 5% and 50%, respectively. Our data
suggest that combination therapy increases bleeding of AN
facilitating their detection with FIT. Another advantage by not
suspending the anticoagulant is that it can also help increase public
participation in CRC screening since discontinuation has been
linked to increased risk of stroke and other adverse cardiovascular
events (Blacker et al, 2003).
This study has certain strengths. First, its database was that of a
prospective clinical trial without selection bias, which should
minimise confounders for the detection of AA and AN. Second,
the number of cases analysed is higher than that reported to date
(Levi et al, 2009; Sawhney et al, 2010; Mandeli et al, 2011). Third,
the original trial was performed with FIT, unlike others which have
used the guaiac faecal occult blood test (Sawhney et al, 2010).
Finally, the study was performed in asymptomatic individuals, in
contrast to other studies (Levi et al, 2009; Sawhney et al, 2010).
The study also has some limitations. First, colonoscopy was not
performed on patients with a negative FIT, so we were not able to
determine the influence OAC drugs may have had on the negative
predictive value of FIT. Second, no information was collected on
prothrombin time-international normalised ratio at the time of the
FIT. Third, other factors such as history of gastrointestinal bleeding
or presence of serious comorbid conditions (acute myocardial
infraction, renal insufficiency and severe anaemia), can interfere
results. Finally, the number of patients in the combined group
(OAC more antiplatelets) with positive FIT and AN were low.
Table 1. Characteristics of individuals included in the study
Users
group
(n¼224)
Non-users
group
(n¼5821) P-value
Positive FIT 21 (9.3%) 365 (6.2%) 0.07
Age (years-old) 62.2 (s.d.: 5.6) 59.4 (s.d.: 5.5) o0.001
Male sex (%) 140 (54.1%) 2663 (46%) 0.003
Proton pump inhibitor 134 (60%) 874 (15%) o0.001
Cardiac disease
Valve prosthesis 28 (12.5%) —
Atrial fibrillation 140 (62.5%) 128 (2.2%) o0.001
Prevention thromboembolism 42 (18.75%) —
Others 14 (6.5%) —
Ischemic stroke-heart 67 (30%) 320 (5.5%) o0.001
Results of colonoscopy
Cancer 1 (4.8%) 19 (5.2%) 0.5
Advanced adenoma 9 (42.9%) 165 (45.2%)
Non-advanced adenoma 4 (19%) 64 (17.5%)
Normal 7 (33.3%) 117 (32.1%)
Location of lesions
Distal 10 (71.5%) 180 (72.6%) 0.5
Proximal 4 (28.5%) 68 (27.4%)
Abbreviation: FIT¼ faecal immunochemical test.
Table 2. Comparison of FIT-positive rate between OACs non-user and
user groups
Indivi-
duals
þFIT,
no. (%) ORa 95% CI P-valueb
Non-users group 5821 365 (6.2) 1 (Ref.)
Users group 224 21 (9.3) 1.3 0.8–2.1 0.3
OAC 164 13 (7.9) 1.15 0.6–2.1 0.6
OACþothers 60 8 (13.3) 1.8 0.8–3.9 0.2
Abbreviations: CI¼ confidence interval; FIT¼ faecal immunochemical test; OAC¼oral
anticoagulant; OR¼odds ratio; Others¼ aspirin p300mgday–1 or clopidogrel.
aOR, comparing users with non-users, adjusted for age and sex.
bCompared with non-users.
Table 3. AN found in each group
Indivi-
duals
AN,
no. (%) ORa 95% CI P-valueb
Non-users group 5821 184 (3.2) 1 (Ref.)
Users group 224 10 (4.5) 1.1 0.5–2.1 0.8
OAC 164 4 (2.4) 0.6 0.2–1.7 0.4
OACþothers 60 6 (10) 2.3 0.9–5.9 0.08
Abbreviations: AN¼ advanced neoplasm; CI¼ confidence interval; FIT¼ faecal immuno-
chemical test; OAC¼oral anticoagulant; OR¼odds ratio; Others¼ aspirin p300mgday–1
or clopidogrel.
aOR, comparing users with non-users, adjusted for age and sex.
bCompared with non-users.
Table 4. Positive predictive value of faecal immunochemical test for AN
according to group and user group
FIT
positive
PPV for
AN
no. (%) OR 95% CI P-valuea
Non-users 365 184 (50.4) 1 (Ref.)
Users group 21 10 (47.6) 0.7 0.3–1.8 0.5
OAC 13 4 (30.8) 0.4 0.1–1.3 0.14
OACþothers 8 6 (75) 2.0 0.4–10.8 0.4
Abbreviations: AN¼ advanced neoplasia; CI¼ confidence interval; OAC¼oral anticoagu-
lants; OR¼odds ratio; Others¼ aspirin p300mgday–1 or clopidogrel; PPV¼ positive
predictive value.
aCompared with non-users and adjusted for age and sex.
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In conclusion, we found that the anticoagulants alone or in
combination with antiplatelet drugs did not reduce the PPV of FIT
for AN. This suggests that OAC therapy should not be
discontinued before stool collection for FIT.
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